Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elamipretide for genetically confirmed Barth syndrome
NL-OMON61412Phase 4Not yet recruiting
- Sponsor
- Stealth BioTherapeutics
- Start
- Jul 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of elamipretide in Barth syndrome (BTHS), sponsored by Stealth BioTherapeutics. Primary endpoint: Composite normalized functional score. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
elamipretide
03
Conditions
Barth syndrome (BTHS)
Beyond the preview
Go deeper on NL-OMON61412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61412.